Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Brown, Jennifer R. [1 ]
Eichhorst, Barbara [2 ]
Ghia, Paolo [3 ,4 ]
Kater, A. P. [5 ]
Li, Jianyong [6 ]
Khurana, Sudha [7 ]
Elhamy, Mostafa [7 ]
Wang, Min Hui [7 ]
Seymour, John F. [8 ,9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Hosp Cologne, Cologne, Germany
[3] Univ Vita Salute Raffaele, Milan, Italy
[4] IRCCS Osped San Raffaele, Milan, Italy
[5] Amsterdam UMC, Amsterdam, Netherlands
[6] Nanjing Med Univ, Affiliated Hosp 1, Jiansu Sheng, Peoples R China
[7] Acerta Pharma, San Francisco, CA USA
[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[9] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
CLL; chronic lymphocytic leukemia; acalabrutinib; Bruton tyrosine kinase inhibitor; combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-092
引用
收藏
页码：S221 / S222
页数：2
相关论文
共 50 条
  • [31] Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
    Kutsch, Nadine
    Pallasch, Christian
    Tausch, Eugen
    Boehme, Volkmar
    Ritgen, Matthias
    Liersch, Ruediger
    Wacker, Alexander
    Jacobs, Georg
    Trappe, Ralf Ulrich
    Dreger, Peter
    Fischer, Kirsten
    Fink, Anna-Maria
    Stilgenbauer, Stephan
    Zhai, Shuyan
    Li, Biao
    Jurgensmeier, Juliane M.
    Rajakumaraswamy, Nishanthan
    Bhargava, Pankaj
    Hallek, Michael
    Eichhorst, Barbara F.
    HEMASPHERE, 2022, 6 (04):
  • [32] Evidence-based investigation of the efficacy and safety of venetoclax-containing regimens versus chemoimmunotherapy in chronic lymphocytic leukemia
    Yao, Pu
    Zhang, Jiao
    Wang, Xiaowen
    Jia, Changsheng
    Cheng, Lin
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025,
  • [33] Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)
    Al-Kali, Aref
    Wierda, William
    Keating, Michael
    O'Brien, Susan
    JOURNAL OF BLOOD MEDICINE, 2010, 1 : 115 - 122
  • [34] BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)
    Levy, Alex
    Jurczak, Wojciech
    Dartigeas, Caroline
    Coscia, Marta
    Ganly, Peter S.
    Al-Jazayrly, Ghassan
    Wang, Chunxiao
    Bao, Katherine
    Leow, Ching Ching
    Shahda, Safi
    Zinzani, Pier Luigi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S269 - S269
  • [35] Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Lavie, David
    Ozcan, Muhit
    Chaudhry, Arvind
    Zhou, Xuan
    Paydar, Ima
    Farooqui, Mohammed Z. H.
    Ghia, Paolo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S353 - S353
  • [36] Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
    Bosch, Francesc
    Cantin, Guy
    Cortelezzi, Agostino
    Knauf, Wolfgang
    Tiab, Mourad
    Turgut, Mehmet
    Zaritskey, Andrey
    Merot, Jean-Louis
    Tausch, Eugen
    Trunzer, Kerstin
    Robson, Susan
    Gresko, Ekaterina
    Boettcher, Sebastian
    Foa, Robin
    Stilgenbauer, Stephan
    Leblond, Veronique
    LEUKEMIA, 2020, 34 (02) : 441 - 450
  • [37] A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients
    Tedeschi, Alessandra
    Rossi, Davide
    Motta, Marina
    Quaresmini, Giulia
    Rossi, Marianna
    Coscia, Marta
    Anastasia, Antonella
    Rossini, Fausto
    Cortelezzi, Agostino
    Nador, Guido
    Scarfo, Lydia
    Cairoli, Roberto
    Frustaci, Anna Maria
    Dalceggio, Daniela
    Picardi, Paola
    De Paoli, Lorenzo
    Orlandi, Ester
    Rambaldi, Alessandro
    Massaia, Massimo
    Gaidano, Gianluca
    Montillo, Marco
    HAEMATOLOGICA, 2015, 100 (12) : E501 - E504
  • [38] Phase 3b Study to Evaluate Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia
    Sharman, Jeff
    Andorsky, David
    Melear, Jason
    Manda, Sudhir
    Anz, Bertrand, III
    Kolibaba, Kathryn
    Yimer, Habte
    Burke, John
    Fanning, Suzanne
    Courtright, Jay
    Islas-Ohlmayer, Miguel
    Kambhampati, Suman
    Jiang, Dingfeng
    Pesko, John
    Vizkelety, Tamas
    Sharmokh, Simon
    Nielsen, Jacqueline
    Flinn, Ian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S219 - S220
  • [39] Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia
    Sharman, Jeff P.
    Miranda, Paulo
    Roos, Jack
    Emeribe, Ugochinyere
    Cai, Ling
    Liljas, Bengt
    Gaitonde, Priyanka
    LEUKEMIA & LYMPHOMA, 2023, 64 (07) : 1243 - 1252
  • [40] Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL
    Munir, T.
    Howard, D. R.
    McParland, L.
    Pocock, C.
    Rawstron, A. C.
    Hockaday, A.
    Varghese, A.
    Hamblin, M.
    Bloor, A.
    Pettitt, A.
    Fegan, C.
    Blundell, J.
    Gribben, J. G.
    Phillips, D.
    Hillmen, P.
    LEUKEMIA, 2017, 31 (10) : 2085 - 2093
12345